<DOC>
	<DOCNO>NCT02600442</DOCNO>
	<brief_summary>A correlation early change tumor maximum standardized uptake value ( SUVmax ) FDG-PET one two cycle neoadjuvant chemotherapy ( NAC ) pathological response 6 8 cycle demonstrate several independent small series patient . Breast tumor proliferation status previously demonstrate good predictive factor response chemotherapy . The best method assess proliferation status unclear . Proportion cell stain nuclear Ki67 antigen widely use assay compare proliferation status tumor . However major variation analytical procedure interpretation limit clinical value . Taking account prognosis predictive value proliferation gene common `` signature '' breast cancer transcriptome analysis , quantitative assessment mRNA expression gene involve proliferation develop investigator team others . The evaluation parameter quantitative reliable standardized clinical use . The main objective investigator study early predict pathological response anthracycline-based neoadjuvant chemotherapy ( NAC ) use combination parameter base FDG-PET image perform baseline 2 cycle , molecular marker proliferation measure pre-treatment biopsy ( Ki67 protein level immunohistochemistry Ki67 mRNA level mRNA ( messenger RNA ) expression pertinent gene Genomic Grade Index ( GGI ) component RT ( reverse transcriptase ) - qPCR ) .</brief_summary>
	<brief_title>Assessment Breast Cancer Response Neoadjuvant Anthracycline-based Chemotherapy FDG-PET Molecular Markers</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women age â‰¥ 18 year Newly diagnose invasive breast cancer StageII stageIII Neoadjuvant anthracyclinebased chemotherapy Primary breast biopsy must available Non metastatic , M0 No prior systemic therapy presFrance : Direction Generale de la Sante ent tumor Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure Metastatic breast cancer Uncontrolled diabetes Limited breast cancer immediately accessible conservative surgery candidate neoadjuvant chemotherapy Previous homolateral breast cancer and/or contralateral breast cancer except treat surgery +/ radiation therapy alone without systemic treatment Any surgery ( include minor procedure lymph node biopsy , primary tumor core biopsy , fine needle aspiration ) within 12 week start study treatment ; fully recover side effect previous procedure . Diagnosis previous malignancy within last 5 year , except adequately treat basal cell carcinoma , squamous cell skin carcinoma , situ cervical carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neoadjuvant Therapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>PET-CT</keyword>
	<keyword>FDG</keyword>
	<keyword>Fluorodeoxyglucose</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Pathological complete response</keyword>
	<keyword>molecular biology</keyword>
	<keyword>proliferation gene</keyword>
</DOC>